COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL NZNZ COCO BUBU More..
Bromhexine study #4 of 5
3/8 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Mikhaylov et al., medRxiv, doi:10.1101/2021.03.03.21252855 (Preprint)
Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study
Source   PDF   Share   Tweet
Small prophylaxis RCT with 25 treatment and 25 control health care worker, showing lower PCR+, symptomatic cases, and hospitalization with treatment, although not statistically significant with the small sample size.

Mikhaylov et al., 3/8/2021, Randomized Controlled Trial, Russia, Asia, preprint, 8 authors.
risk of hospitalization, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 25 (0.0%), control 2 of 25 (8.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of symptomatic case, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no virological cure, 71.4% lower, RR 0.29, p = 0.14, treatment 2 of 25 (8.0%), control 7 of 25 (28.0%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 5 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.